Lutikizumab Biosimilar Bispecific Dual-Variable-Domain Antibody (IL-1α × IL-1β) for Research
Pre-Made Lutikizumab biosimilar, Bispecific Dual Variable Domain IG, Anti-IL1A;IL1B Antibody: Anti-IL1/IL-1A/IL1F1/IL1-ALPHA/IL-1 alpha;IL-1/IL1-BETA/IL1F2/IL1beta therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-331-1mg | 1mg | |
| GMP-Bios-ab-331-10mg | 10mg | |
| GMP-Bios-ab-331-100mg | 100mg | |
| GMP-Bios-ab-331-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Lutikizumab biosimilar, Bispecific Dual Variable Domain IG, Anti-IL1A;IL1B Antibody: Anti-IL1/IL-1A/IL1F1/IL1-ALPHA/IL-1 alpha;IL-1/IL1-BETA/IL1F2/IL1beta therapeutic antibody |
| INN Name | Lutikizumab |
| Target | IL1A;IL1B |
| Format | Bispecific Dual Variable Domain IG |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Abbott Laboratories;AbbVie |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Osteoarthritis |
| Development Tech | Dual Variable Domain Immunoglobulin Technology |
About target - IL1A
1. Protein Interleukin-1 alpha
2. Gene IL1A
3. Organism Homo sapiens (Human)
Function
Produced by activated macrophages, IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity. IL-1 proteins are involved in the inflammatory response, being identified as endogenous pyrogens, and are reported to stimulate the release of prostaglandin and collagenase from synovial cells.

